CLINICAL_TRIALS
trial_result
· 2022-12-28
Clinical Trial Update: PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA [Phase 2]
Summary
A Phase 2 placebo-controlled safety study of ritlecitinib (PF-06651600) in adults with alopecia areata was terminated, and the results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Alopecia Areata | Phase 2 | Status: TERMINATED | Results posted: 2022-12-28